-
Hillstream BioPharma Progressing Towards Acquiring Clinical Stage Asset and Announces Corporate Name Change to Tharimmune, Inc.
Hillstream BioPharma Progressing Towards Acquiring Clinical Stage Asset and Announces Corporate Name Change to Tharimmune, Inc. September 22, 2023 Expects to launch and complete a Phase 1 trial in Q4 2023 Tharimmune…September 22, 2023 -
Dawson James Securities Announces October Date for 8th Annual Small Cap Growth Conference
Dawson James Securities Announces October Date for 8th Annual Small Cap Growth Conference September 21, 2023 JUPITER, Fla., Sept. 21, 2023 (GLOBE NEWSWIRE) -- via InvestorWire -- Dawson James Securities, Inc. (“Dawson”), a full-service…September 21, 2023 -
Hillstream Enters into an Exclusive Option Agreement to Acquire a Clinical Stage Asset for Chronic Pruritis
Hillstream Enters into an Exclusive Option Agreement to Acquire a Clinical Stage Asset for Chronic Pruritis September 11, 2023 Anticipate completion of Phase 1 & Phase 2 clinical trials in chronic pruritis…September 11, 2023 -
Hillstream Advances Next-Gen Multispecific Antibodies for Solid Tumors with Lead HER2/HER3 Program, HSB-3215
Hillstream Advances Next-Gen Multispecific Antibodies for Solid Tumors with Lead HER2/HER3 Program, HSB-3215 July 20, 2023 Collaboration adds multiple modular swappable antigen recognition regions to lead program, HSB-3215, a bispecific antibody targeting…July 20, 2023 -
Hillstream BioPharma Announces Strategic Reprioritization of Pipeline to Targeting HER2/HER3 Solid Tumors via Bispecific and ADC Antibodies and Biologics
Hillstream BioPharma Announces Strategic Reprioritization of Pipeline to Targeting HER2/HER3 Solid Tumors via Bispecific and ADC Antibodies and Biologics July 10, 2023 Lead bispecific antibody, HSB-3215 designed to target novel conformational epitopes…July 10, 2023 -
Hillstream BioPharma Licenses Technology to Develop Proprietary HER2 and HER3 Antibody Drug Conjugates against Drug-Resistant Breast, Lung, Gastric, and Ovarian Cancers
Hillstream BioPharma Licenses Technology to Develop Proprietary HER2 and HER3 Antibody Drug Conjugates against Drug-Resistant Breast, Lung, Gastric, and Ovarian Cancers July 06, 2023 Anti-HER2 and Anti-HER3 monoclonal antibodies designed to have…July 6, 2023 -
Hillstream BioPharma Strengthens its Board of Directors with Appointment of Kelly Anderson
Hillstream BioPharma Strengthens its Board of Directors with Appointment of Kelly Anderson May 15, 2023 Appointment to Enhance Board’s Expertise Across Investments, Business Development and Capital Markets BRIDGEWATER, N.J., May 15, 2023 (GLOBE…May 15, 2023 -
Hillstream BioPharma Regains Compliance with Nasdaq Listing Minimum Bid Price Rule
Hillstream BioPharma Regains Compliance with Nasdaq Listing Minimum Bid Price Rule February 15, 2023 Company Hosted its R&D Day to Discuss Product and Pipeline Goals Across 4 Pipeline Candidates and its Quatramer™ Tumor-Targeting…February 15, 2023 -
Hillstream BioPharma Signs Exclusive Option Agreement with Applied Biomedical Science Institute (ABSI) to License Technology for HER2 and HER3 to be Developed for Potential Treatments Against Drug Resistant Cancers Including HER2-Positive Metastatic Breast Cancer, Gastric Cancer, Lung Cancer and Ovarian Cancer
Hillstream BioPharma Signs Exclusive Option Agreement with Applied Biomedical Science Institute (ABSI) to License Technology for HER2 and HER3 to be Developed for Potential Treatments Against Drug Resistant Cancers Including HER2-Positive Metastatic…February 13, 2023 -
In a KRAS G12C-mutated NSCLC cell line, Calu-1, Hillstream BioPharma Demonstrated Significantly Greater Tumor Inhibition Combining Pembrolizumab, an anti-PD-1 antibody, and HSB-1216, a Ferroptosis Inducer
In a KRAS G12C-mutated NSCLC cell line, Calu-1, Hillstream BioPharma Demonstrated Significantly Greater Tumor Inhibition Combining Pembrolizumab, an anti-PD-1 antibody, and HSB-1216, a Ferroptosis Inducer February 10, 2023 Synergy and crosstalk between…February 10, 2023
Loading posts...
Recent Posts
- Hillstream BioPharma Progressing Towards Acquiring Clinical Stage Asset and Announces Corporate Name Change to Tharimmune, Inc.
- Dawson James Securities Announces October Date for 8th Annual Small Cap Growth Conference
- Hillstream Enters into an Exclusive Option Agreement to Acquire a Clinical Stage Asset for Chronic Pruritis
- Hillstream Advances Next-Gen Multispecific Antibodies for Solid Tumors with Lead HER2/HER3 Program, HSB-3215
- Hillstream BioPharma Announces Strategic Reprioritization of Pipeline to Targeting HER2/HER3 Solid Tumors via Bispecific and ADC Antibodies and Biologics